Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTanfield Regulatory News (TAN)

Share Price Information for Tanfield (TAN)

Share Price is delayed by 15 minutes
Get Live Data
5.33    0.57 (11.97%)
Bid:
4.76
Ask:
5.90
Spread: 1.14 (23.95%)
Market Cap: £7.75m
TAN Live PriceLast checked at - London Stock Exchange

Intraday Tanfield Share Chart

Loan Subscription Update

3 Mar 2022 12:56

RNS Number : 5580D
Tanfield Group PLC
03 March 2022
 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain

 

 

Tanfield Group Plc

("Tanfield" or the "Company")

 

Loan Subscription Update

 

 

The Board of Tanfield (the "Board") is pleased to update the market with respect to additional loans put in place to fund the Company's ongoing legal proceedings in relation to its investment in Snorkel International Holdings LLC ("Snorkel"), the aerial work platform business, and other day to day costs.

 

Investment Background

 

· Tanfield is a 49% shareholder in the equity of Snorkel following the joint venture between the Company and Xtreme Manufacturing LLC ("Xtreme") (the "Contemplated Transaction"), a company owned by Don Ahern of Ahern Rentals Inc, relating to Snorkel, in October 2013.

 

· The Snorkel investment is valued at £19.1m. The outcome of the US and UK Proceedings referenced below could have an impact on this valuation.

 

· On 22 October 2019, the Company announced that it had received a Summons and Complaint, filed in Nevada (the "US Proceedings") by subsidiaries of Xtreme, relating to the Contemplated Transaction.

 

· On 24 October 2019, the Company announced it had become necessary to issue and serve a claim in the English High Court against Ward Hadaway (the "UK Proceedings"), the solicitor acting for the Company at the time of the Contemplated Transaction, in order to fully protect the Company's rights pending the outcome of the US Proceedings.

 

· On 26 February 2021, Ward Hadaway were granted permission to join Foulston Siefkin LLP ("Foulston Siefkin"), Tanfield's US based law firm who were retained in 2013 to draft the documents governed by US law relating to the Contemplated Transaction, into the UK Proceedings. As a result, the Company amended its claim to include Foulston Siefkin as a second defendant.

 

 

Loan Subscription

 

Further to the update on 3 June 2021, in which the Company announced that the second loan note instrument (the "Second Loan") of up to £1m had subscriptions totalling £950,000, and the update on 30 March 2020, in which the Company announced the first loan note instrument (the "First Loan") of up to £700,000, with £500,000 initially being subscribed to, the Board is pleased to announce that an additional £125,000 of the First Loan has now been subscribed to, taking the total First Loan subscription value to £625,000. The additional First Loan (the "Additional Loan") will be used for providing ongoing funding for the US and UK Proceedings and other day to day costs.

 

The Additional Loan is unsecured and carries annual interest of 10% which is to accrue and is repayable on the earlier of (i) 28 February 2025 or (ii) receipt of sufficient funds relating to either the US or UK Proceedings. Should repayment take place prior to 28 February 2025, a 20% early redemption premium shall apply.

 

A number of existing shareholders have subscribed to the Additional Loan of £125,000, which constitutes a related party transaction under Rule 13 of the AIM Rules as a result of OTK Holding A/S and Zoar Invest Aps, which each hold approximately 14% of the issued shares of the Company, subscribing £50,000 each to the Additional Loan. The Directors of the Company, having consulted with WH Ireland Limited, the Company's nominated adviser, consider the terms of the transaction to be fair and reasonable in so far as shareholders are concerned.

 

Following discussions with the existing shareholders, the Board are of the opinion that further loan funding may be necessary to ensure that the Company can continue to protect its investment in Snorkel.

 

The Board believe that a positive outcome to either or both of the US Proceedings and UK Proceedings is a reasonable expectation, and the Company will continue to vigorously defend and advance its position in both proceedings, whilst continuing to seek advice. 

 

Further updates will be provided to Shareholders as and when appropriate.

 

 

 

For further information:

 

Tanfield Group Plc 020 7220 1666

Daryn Robinson  

 

WH Ireland Limited - Nominated Advisor / Broker

James Joyce / Ben Good 020 7220 1666

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKNBPBBKDNNK
Date   Source Headline
17th Oct 20194:35 pmRNSPrice Monitoring Extension
26th Sep 20197:00 amRNSChange of Registered Office
21st Aug 20197:00 amRNSInterim Results
16th Aug 20194:00 pmRNSSnorkel Investment Update
22nd Jul 20197:00 amRNSResult of AGM
21st Jun 201912:40 pmRNSPosting of Annual Report and Notice of AGM
13th Jun 20197:00 amRNSFinal Results for 31 Dec 18 and Notice of AGM
5th Jun 20197:00 amRNSHolding(s) in Company
5th Jun 20197:00 amRNSHolding(s) in Company
31st May 201910:08 amRNSIssue of shares
29th May 20194:35 pmRNSPrice Monitoring Extension
22nd May 201911:23 amRNSSnorkel Investment Update
7th May 201912:57 pmRNSSnorkel Investment Update
15th Mar 201912:07 pmRNSSecond Price Monitoring Extn
15th Mar 201912:02 pmRNSPrice Monitoring Extension
14th Mar 20194:41 pmRNSSecond Price Monitoring Extn
14th Mar 20194:35 pmRNSPrice Monitoring Extension
13th Mar 20194:40 pmRNSSecond Price Monitoring Extn
13th Mar 20194:35 pmRNSPrice Monitoring Extension
15th Jan 201911:58 amRNSSnorkel Investment Update
22nd Nov 20183:56 pmRNSSnorkel Investment Update
22nd Oct 20181:43 pmRNSSnorkel Investment Update
4th Oct 20184:41 pmRNSSecond Price Monitoring Extn
4th Oct 20184:35 pmRNSPrice Monitoring Extension
28th Sep 20187:00 amRNSInterim Results
21st Sep 20184:40 pmRNSSecond Price Monitoring Extn
21st Sep 20184:35 pmRNSPrice Monitoring Extension
20th Sep 20187:00 amRNSSnorkel Investment Update
10th Sep 20184:40 pmRNSSecond Price Monitoring Extn
10th Sep 20184:35 pmRNSPrice Monitoring Extension
7th Sep 20184:40 pmRNSSecond Price Monitoring Extn
7th Sep 20184:35 pmRNSPrice Monitoring Extension
6th Sep 20184:40 pmRNSSecond Price Monitoring Extn
6th Sep 20184:35 pmRNSPrice Monitoring Extension
6th Sep 201810:15 amRNSSnorkel Investment Update
13th Jul 20187:00 amRNSCorporate Update
6th Jul 20184:40 pmRNSSecond Price Monitoring Extn
6th Jul 20184:35 pmRNSPrice Monitoring Extension
21st Jun 20184:16 pmRNSSnorkel Investment Update
22nd May 20182:24 pmRNSResult of AGM
30th Apr 201810:26 amRNSDirector/PDMR Shareholding
24th Apr 20187:00 amRNSFinal Results
10th Apr 201810:59 amRNSSnorkel Investment Update
26th Feb 20183:30 pmRNSHolding(s) in Company
26th Feb 201810:32 amRNSHolding(s) in Company
22nd Feb 20182:23 pmRNSIssue of shares and appointment of sole broker
29th Nov 20174:40 pmRNSSecond Price Monitoring Extn
29th Nov 20174:35 pmRNSPrice Monitoring Extension
20th Nov 20177:00 amRNSSnorkel Investment Update
31st Oct 201712:15 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.